ArriVent BioPharma, Inc.

NASDAQ: AVBP · Healthcare · Biotechnology

PublicHQ Newtown Square, PACIK 0001868279Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 57DQ —GM —SS 50

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$166.3M

Employees

Market cap

$1.6B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$166.3M-$166.3M2025

Operating income-$177.5M-$177.5M2025

Total assets$333.2M$333.2M2025

Liabilities$25.9M$25.9M2025

Equity$307.2M$307.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

ArriVent BioPharma, Inc. earned -$166.3M in FY2025 net income.

Peers · Healthcare

AtriCure, Inc.84B+Innovage Holding Corp.68B Novavax, Inc.69B Taysha Gene Therapies, Inc.47D

Key facts

CEOZhengbin Yao

SectorHealthcare

IndustryBiotechnology

HeadquartersNewtown Square, PA

ExchangeNASDAQ: AVBP

Employees77

IPO date2024-01-26

Latest filings

8-K2026-06-22 10-Q2026-05-11 8-K2026-05-11 8-K2026-05-11 DEF 14A2026-04-28 8-K2026-03-17 8-K2026-03-05 10-K2026-03-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.